Meta-analysis of results from eight randomized, placebo-controlled trials of the effect of cilostazol on patients with intermittent claudication

Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management

“…126 Cilostazol was superior to placebo in most studies performed to date. Dawson et al 128 compared the efficacy and safety of cilostazol (100 mg twice daily) to pentoxifylline (400 mg 3 times daily) in patients with intermittent claudication.…”

“…It may also cause an increase in high-density lipoprotein cholesterol levels and a decrease in triglyceride levels. 126 Because cilostazol is a phosphodiesterase inhibitor similar to milrinone, it is contraindicated (black box warning) in patients with a history of congestive heart failure or in patients with an ejection fraction of less than 40%. 4 Long-term use of oral milrinone in cardiomyopathic patients was associated with increased mortality.…”

Concomitant Peripheral Arterial Disease and Coronary Artery Disease

“…The use of cilostazol (a type III phosphodiesterase inhibitor) 41 and supervised exercise programs 42 have all been associated with improvement in walking distance in patients with claudication caused by peripheral arterial disease. Preliminary data suggest a potential benefit of cholesterol lowering with atorvastatin, but the clinical significance of this remains unclear.…”

Cilostazol, um inibidor da fosfodiesterase III: perspectivas futuras na aterosclerose

“…1 Study results demonstrate the superiority of cilostazol in comparison to placebo and pentoxifylline to increase walking distance without pain in 50% of the patients, and the maximum walking distance in 64% of the patients 2 , thus improving quality of life 3 . This medication is an antithrombotic antiplatelet agent 4 with vasodilation action 5 .…”